Stock Research for ATOS

ATOS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATOS Stock Chart & Research Data

The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATOS Due diligence Resources & Stock Charts

The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATOS Detailed Price Forecast - CNN Money CNN View ATOS Detailed Summary - Google Finance
Yahoo View ATOS Detailed Summary - Yahoo! Finance Zacks View ATOS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ATOS Trends & Analysis - Trade-Ideas Barrons View ATOS Major Holders - Barrons
NASDAQ View ATOS Call Transcripts - NASDAQ Seeking View ATOS Breaking News & Analysis - Seeking Alpha
Spotlight View ATOS Annual Report - CompanySpotlight.com OTC Report View ATOS OTC Short Report - OTCShortReport.com
TradeKing View ATOS Fundamentals - TradeKing Charts View ATOS SEC Filings - Bar Chart
WSJ View Historical Prices for ATOS - The WSJ Morningstar View Performance/Total Return for ATOS - Morningstar
MarketWatch View the Analyst Estimates for ATOS - MarketWatch CNBC View the Earnings History for ATOS - CNBC
StockMarketWatch View the ATOS Earnings - StockMarketWatch MacroAxis View ATOS Buy or Sell Recommendations - MacroAxis
Bullish View the ATOS Bullish Patterns - American Bulls Short Pains View ATOS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ATOS Stock Mentions - StockTwits PennyStocks View ATOS Stock Mentions - PennyStockTweets
Twitter View ATOS Stock Mentions - Twitter Invest Hub View ATOS Investment Forum News - Investor Hub
Yahoo View ATOS Stock Mentions - Yahoo! Message Board Seeking Alpha View ATOS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ATOS - SECform4.com Insider Cow View Insider Transactions for ATOS - Insider Cow
CNBC View ATOS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATOS - OTC Markets
Yahoo View Insider Transactions for ATOS - Yahoo! Finance NASDAQ View Institutional Holdings for ATOS - NASDAQ


Stock Charts

FinViz View ATOS Stock Insight & Charts - FinViz.com StockCharts View ATOS Investment Charts - StockCharts.com
BarChart View ATOS Stock Overview & Charts - BarChart Trading View View ATOS User Generated Charts - Trading View




Latest Financial News for ATOS


An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"
Posted on Friday September 14, 2018

SAN FRANCISCO, CA / ACCESSWIRE / September 14, 2018 / The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...


Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
Posted on Thursday September 13, 2018

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen. “Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy,” commented Dr. Steven C. Quay, CEO and President. “We anticipate retaining a clinical research organization to manage that study in the fourth quarter 2018.


Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT
Posted on Wednesday September 12, 2018

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 24 healthy male subjects. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of topical Endoxifen at varying dose levels over 28 days. Callers should ask to be joined into the Atossa Genetics call.


''Robust Economy, Resilient Market''
Posted on Thursday August 23, 2018

SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2018 / Vista Partners ("Vista") has published August's FREE Macroeconomic & Investment Monthly Newsletter, "Robust Economy, Resilient Market." ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.